+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Baculoviral IAP Repeat Containing Protein"

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H2 2019 - Product Thumbnail Image

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H2 2019

  • Drug Pipelines
  • November 2019
  • 83 Pages
  • Global
From
Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019 - Product Thumbnail Image

Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

  • Drug Pipelines
  • August 2019
  • 88 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

The Baculoviral IAP Repeat Containing Protein (BIRC) market is a subset of the oncology drug market. BIRC proteins are a family of proteins that are involved in the regulation of apoptosis, or programmed cell death. They are used in the treatment of cancer, as they can inhibit the growth of cancer cells and induce apoptosis. BIRC proteins are also used in the development of cancer vaccines, as they can stimulate the immune system to recognize and attack cancer cells. BIRC proteins are also used in the development of gene therapies, as they can be used to deliver therapeutic genes to cancer cells. Companies in the BIRC market include Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more